For almost a century, we have successfully leveraged our core capabilities in engineering, formulating, developing and delivering protein-based treatments for those living with serious, chronic diseases, primarily based on our core technology platforms: peptides and proteins.
To ensure future success of our discovery processes, we continuously strengthen our capabilities and invest in emerging and cutting-edge technologies. Today, we have technology platforms covering a number of core areas, which are essential to drive innovation across the diseases we target.
Once a target has been identified and validated, the next step is to find molecules that might inhibit or enhance the target’s activity. Current techniques allow many thousands of compounds to be screened quickly. Compounds that initially show the effect we want are called 'hits'.
We refine hits by testing their efficacy and safety in many different ways, and only the very best molecules will make it all the way through the research and development pipeline to become medicines – those molecules which have an efficacious effect on a disease and which don’t show significant negative side effects, but are safe to be taken.
It is an extensive and rigorous process that can take 10-15 years (or more), from the initial idea to advancement through clinical development and finally receiving approval from regulators.
The stakes are high to get the correct target from the very beginning and to develop a treatment towards it. To do this, we rely on our research technology platforms that drive innovation and provide us with the techniques, methods and processes that enhance our accuracy and search.